Search results
Simtuzumab (GS-6624) in the Treatment of Cirrhosis Due to NASH
… Double-Blind Phase Open Label Phase (optional) Trial Website: https://clinicaltrials.gov/show/NCT01672879 …
Last Modified:
Prospective Randomized Double Blind Placebo Controlled Trial of Rifaximin 550mg PO Twice Daily for Three Months to Prevent Recurrent Fibrosis in Liver Transplant Recipients with Chronic Hepatitis C Virus Infection
… the study for approximately 1 year post transplant. Trial Website: https://clinicaltrials.gov/show/NCT01603108 …
Last Modified:
Maribavir for Treatment of Resistant or Refractory CMV Infections in Transplant Recipients
… recipients of stem cell or solid organ transplants. Trial Website: https://clinicaltrials.gov/show/NCT01611974 …
Last Modified: